The heterodimeric transcription factor HIF-2 is arguably the most important driver of clear cell renal cell carcinoma (ccRCC). While considered undruggable, structural analyses at UT Southwestern Medical Center (UTSW) identified a vulnerability in the a subunit, which heterodimerizes with HIF-1b, ultimately leading to the development of PT2385, a first-in-class inhibitor.

X